FDA approves Egrifta for treatment of lipodystrophy in people with HIV
The US Food and Drug Administration announced yesterday that it has approved Egrifta for the treatment of lipodystrophy in people with HIV.
Results from a recent large study indicate that current or recent protease inhibitor use does not increase the risk of stroke or sudden death in people with HIV.